Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (Stage III and IV) non-small cell lung cancer

Neoplasma

Volumn 57, Issue 3, 2010, Pages 241-246

  Kim, Y S ^a   Lee, M K ^a   Kim, S J ^a   Kim, I J ^a   Kim, Y K ^a   Jo, W S ^a   Park, S K ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Chemotherapy; F 18 FDG PET CT; Non small cell lung cancer; Survival

Indexed keywords

CARBOPLATIN; DOCETAXEL; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; PACLITAXEL; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; LUNG TUMOR; MIDDLE AGED; MORTALITY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77954645377     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_03_241     Document Type: Review

References (26)

1. JEMAL A, SIEGEL R, WARD E, HAO Y, XU J, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. doi:10.3322/CA.2007.0010
2. MOUNTAIN CF. Revisions in the international system for lung cancer staging. Chest 1997; 111: 1710-1717. doi:10.1378/ chest.111.6.1710
3. HOEKSTRA CJ, STROOBANTS SG, SMIT EF, VANSTEENKISTE J, VAN TINTEREN H, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 8362-8370. doi:10.1200/JCO.2005.01.1189
4. MANUS MM, HICKS RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: A critical review. Int J Radiat Oncol Biol Phys 2008; 72: 1298-1306. doi:10.1016/ j.ijrobp.2008.08.022
5. HOANG JK, HOAGLAND LF, COLEMAN RE, COAN AD, HERDON II JE, et al. Prognosti value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008; 26: 1459-1464. doi:10.1200/JCO.2007.14.3628
6. DECOSTER L, SCHALLIER D, EVERAERT H, NIEBOER K, MEYSMAN M, et al. Complete metabolic tumor response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced nonsmall cell lung cancer (NSCLC). Lung Cancer 2008; 62: 55-61. doi:10.1016/j.lungcan.2008.02.015
7. HANIN FX, LONNEUX M, CORNET J, NOIRHOMME P, COULON C, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008; 33: 819-823. doi:10.1016/j.ejcts.2008.02.005
8. DOOMS C, VERBEKEN E, STROOBANTS S, NACKAERTS K, DE LEYN P, et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: A model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008; 26: 1128-1134. doi:10.1200/ JCO.2007.13.9550
9. XU X, YU J, SUN X, LI K, FU Z, et al. The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III nonsmall cell lung cancer. Am J Clin Oncol 2008; 31: 470-475. doi:10.1097/COC.0b013e31816fc943
10. MAC MANUS MP, HICKS RJ, MATTHEWS JP, MCKENZIE A, RISCHIN D, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21: 1285-1292. doi:10.1200/JCO.2003.07.054
11. de GEUS-OEI LF, VAN DER HEIJDEN HF, VISSER EP, HERMSEN R, VAN HOORN BA, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007; 48: 1592-1598. doi:10.2967/jnumed.107.043414
12. THERASSE P, ARBUCK SG, EISENHAUSER EA, WANDERS J, KAPLAN RS, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. doi:10.1093/ jnci/92.3.205
13. SOBHANI I, TIRET E, LEBTAHI R, APARICIO T, ITTI E, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008; 98: 875-880. doi:10.1038/sj.bjc.6604263
14. KASPER B, DIETRICH S, DIMITRAKOPOULOU-STRAUSS A, STRAUSS LG, HABERKORN U, et al. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie 2008; 31: 107-112. doi:10.1159/000113795
15. WAKABAYASHI H, NISHIYAMA Y, OTANI T, SANO T, YACHIDA S, et al. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterology 2008; 14: 64-69. doi:10.3748/wjg.14.64
16. DOWNEY RJ, AKHURST T, GONEN M, VINCENT A, BAINS MS, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22: 3255-3260. doi:10.1200/JCO.2004.11.109
17. SASAKI R, KOMAKI R, MACAPINLAC H, ERASMUS J, ALLEN P, et al. [18F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23: 1136-1143. doi:10.1200/ JCO.2005.06.129
18. OHTSUKA T, NOMORI H, WATANABE K, KAJI M, NARUKE T, et al. Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic Stage I lung adenocarcinoma. Cancer 2006; 107: 2468-2473. doi:10.1002/cncr.22268
19. ESCHMANN SM, FRIEDEL G, PAULSEN F, REIMOLD M, HEHR T, et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with Stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 2006; 33: 263-269. doi:10.1007/s00259-005-1953-2
20. DAVIES A, TAN C, PASCHALIDES C, BARRINGTON SF, O'DOHERTY M, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 2007; 55: 75-78. doi:10.1016/j.lungcan.2006.09.010
21. PÖTTGEN C, LEVEGRUN S, THEEGARTEN D, MARNITZ S, GREHL S, et al: Value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in nonsmall cell lung cancer for prediction of pathologic response and times to relapse after neo-adjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97-106. doi:10.1158/1078-0432. CCR-05-0510
22. ESCHMANN SM, FRIEDL G, PAULSEN F, REIMOLD M, HEHR T, et al: Repeat (18)F-FDG-PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2007; 55: 165-171. doi:10.1016/ j.lungcan.2006.09.028
23. CERFOLIO RJ, BRYANT AS, WINOKUR TS, OHJA B, BARTOLUCCI AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004; 78: 1903-1909. doi:10.1016/j.athoracsur.2004.06.102
24. SCHMIDT M, BOLLSCHWEILER E, DIETLEIN M, MÖNIG SP, KOBE C, et al. Mean and maximum standardized uptake values in [18F] FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging 2009; 36: 735-744. doi:10.1007/s00259-008-1011-y
25. MIN KYOUNG KIM, JIN-SOOK RYU, SUNG-BAE KIM, JIN HEE AHN, SOO YOUNG KIM, et al. Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 2007; 43: 1385-1391. doi:10.1016/j.ejca.2007.04.001
26. ROSENBERG R, HERRMANN K, GERTLER R, KÜNZLI B, ESSLER M, et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis 2009; 24: 191-200. doi:10.1007/s00384-008-0616-8